12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Company News  |  Deals

BrainStorm, Octane Medical Group deal

The companies partnered to co-develop a proprietary bioreactor to produce BrainStorm's NurOwn NTF stem cells using Octane Biotech Inc.'s Automated Cell & Tissue Engineering System (ACTES) technology. The project...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >